Treatment with vedolizumab appears to induce clinical remission and/or mucosal healing in a considerable number of patients with moderate to severe Crohn’s disease (CD), with only minor cases of adverse-event-related discontinuation, according to data from the US VICTORY Consortium. Researchers followed 212 patients with moderate to severe CD (median age 34 years; 60 percent female) who were treated with vedolizumab for an average of 39 weeks. Majority of the patients were exposed to tumour necrosis factor (TNF)-antagonist (90 percent).
Study outcomes were clinical remission or mucosal healing, serious infection, and serious adverse events. The 12-month cumulative rate was 35 percent for clinical remission, 63 percent for mucosal healing, and 26 percent for deep remission (clinical remission and mucosal healing). Patients who were less likely to achieve clinical remission included those…
